RNU6-65P

Across TCGA pan-cancer cohorts, RNU6-65P RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated RNU6-65P data layer.

The strongest signal is observed in testicular germ cell tumors (TGCT), where higher RNU6-65P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-65P expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

TGCT, SARC, and LGG are the cancer types where RNU6-65P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
TGCT	DFS	Tertile	All	0.035	0.837	<.001	18	view →
SARC	OS	Tertile	All	0.133	0.860	<.001	18	view →
LGG	OS	Tertile	All	0.409	0.836	<.001	18	view →
BRCA	OS	Tertile	All	0.185	0.579	.037	12	view →
THCA	DFS	Tertile	II,III,IV	0.650	0.907	.044	9	view →
ESCA	OS	Tertile	III,IV	1.000	0.376	.048	6	view →
KIRP	OS	Tertile	All	0.634	0.948	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RNU6-65P–TGCT (DFS)

Open the TGCT breakdown →